Lymphoma in the News: Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent Non-Hodgkin Lymphoma « New Developments in Lymphoma
Links shared publicly online about this topic.
- 128total visits
Lymphoma in the News: Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent Non-Hodgkin Lymphoma « New Developments in Lymphoma
Lymphoma in the News: Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent Non-Hodgkin Lymphoma « New Developments in Lymphoma
View full resource at cornell-lymphoma.com
Tags: Cancer, Lymphoma, Non-Hodgkin Lymphoma Medication, Rheumatoid Arthritis Medication, Rituxan, MabThera, News
Most Recently Shared on July 22, 2011 at 1:36 pm By:
Lenalidomide Plus Rituximab Shows Promise as First-Line Therapy in Patients with Indolent #Lymphoma http://t.co/NK7NvgG
Advertisement
